FigureAsia 35 Under 35 · Healthcare
Jethtavuth “Ben” Sartproong
Age 30 · Healthcare navigation and procedure marketplace · Bangkok, Thailand
Thai founder whose platform reported more than 500,000 patients navigated, 30,000 procedures and a 3,000-provider network across Thailand and Indonesia in 2025.
- Approximate age at 31 December 2025
- 30
- Field
- Healthcare
- Country or region
- Bangkok, Thailand
- FigureAsia U35 Assessment
- 84.0 / 100
Profile
Career and documented record
Jethtavuth Sartproong has built healthcare navigation for markets where price, availability and provider information are often difficult to compare. In 2025, the platform he cofounded reported more than 500,000 patients navigated, over 30,000 procedures and a network exceeding 3,000 providers across Thailand and Indonesia. A financing round supported further regional and AI-enabled expansion.
The service spans preventive, elective and cosmetic categories, so its scale cannot be equated with treatment of serious disease. Nor do bookings establish quality, appropriateness or improved outcomes. Its contribution is transactional clarity: helping people find, compare and schedule services in a fragmented private-care environment while giving providers a channel to use spare capacity.
Sartproong's individual role is documented as cofounder and operating leader. The public evidence is mostly company-reported, which limits the strength of the available evidence. FigureAsia includes him because the reported reach is material and the access problem is real, while making no claim that marketplace volume alone equals healthcare quality.
FigureAsia selection
Why Jethtavuth “Ben” Sartproong is on the list
FigureAsia selected Sartproong because he has built a regionally scaled service around information and scheduling friction that patients in Southeast Asia experience every day. The ranking recognizes operating reach and founder agency, not the number of bookings as a clinical endpoint. Greater transparency on quality, adverse events, provider standards and audited usage would strengthen future evaluation.
Verified work
The 2025–26 record
Principal milestone
More than 500,000 patients reportedly navigated
Evidence record
More than 30,000 procedures reportedly booked
Scale or implementation
More than 3,000 providers across two countries
Field context
The work in its field
Within healthcare navigation and procedure marketplace, the relevant test is whether a result can survive scrutiny of maturity, attribution, validity and practical fit. That distinction matters: completed evidence is not projected benefit, and individual responsibility is not interchangeable with the wider team’s achievement.
FigureAsia U35 Assessment
Assessment breakdown
84.0out of 100
Substantive 2025–2026 contribution
16 / 20
The score reflects completed 2025–26 work in healthcare navigation and procedure marketplace, assessed at the documented maturity of deployed regional healthcare marketplace.
Verified impact
13.5 / 15
Impact credit is limited to the measured study, regulatory, implementation or operating record stated in the profile; unsupported patient benefit is excluded.
Originality and distinction
7 / 10
The work creates or materially advances a distinctive capability within healthcare navigation and procedure marketplace rather than relying on title or institutional association.
Field and industry influence
8 / 10
The assessment recognises demonstrated effects on research, product development, care delivery or professional practice, with publicity alone carrying no weight.
Individual agency
9 / 10
Named authorship and the documented role of Cofounder and Vice President establish individual responsibility while preserving credit for collaborators.
Durability and trajectory
4 / 5
The cited work forms part of a continuing programme, platform or research trajectory rather than a single uncompleted announcement.
Asian significance and global relevance
5 / 5
The Asian connection is material to the person's identity, operating base or populations served: Thai founder operating across Thailand and Indonesia.
Clinical and scientific validity
4.9 / 7
Clinical and scientific validity is calibrated to deployed regional healthcare marketplace, with the profile retaining the evidence boundary attached to the result.
Safety, quality and responsible governance
5.6 / 7
Safety and governance credit reflects accurate regulatory language, study limitations, data stewardship and the refusal to turn early evidence into clinical certainty.
Translation and care-pathway fit
6 / 6
The work is scored for its demonstrated fit with a laboratory, regulatory, clinical, operational or public-health pathway, not for projected future adoption.
Access, equity and resource stewardship
5 / 5
Access credit reflects documented reach, capacity, affordability or inclusion while distinguishing service volume from proven clinical outcome.